News
KRON
1.000
+2.04%
0.020
5 Microcap Stocks With 65% or More Upside Potential
NASDAQ · 2d ago
Kronos Bio To Present Clinical Update On Phase 1/2 Trial Of KB-0742 At The 2024 ASCO Annual Meeting
Kronos Bio, Inc. Will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors at the American Society of Clinical Oncology Annual Meeting in 2024. The company will present data from the ongoing Phase 1/2 trial.
Benzinga · 4d ago
Weekly Report: what happened at KRON last week (0415-0419)?
Weekly Report · 6d ago
Weekly Report: what happened at KRON last week (0408-0412)?
Weekly Report · 04/15 09:15
Weekly Report: what happened at KRON last week (0401-0405)?
Weekly Report · 04/08 09:16
Weekly Report: what happened at KRON last week (0325-0329)?
Weekly Report · 04/01 09:16
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 03/27 16:00
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Axsome Therapeutics (AXSM) and Sotera Health (SHC)
TipRanks · 03/26 10:40
Weekly Report: what happened at KRON last week (0318-0322)?
Weekly Report · 03/25 09:16
Kronos Bio’s Restructuring Risks: Cost Cuts Versus Operational Efficiency
TipRanks · 03/22 06:01
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023
Kronos Bio reported earnings per share of -43 cents for the fourth quarter of 2023. The company reported revenue of $2.29 million. This was 50.39% better than the analyst estimate for revenue. Kronos Bio is a biotechnology company.
Investorplace · 03/21 17:53
Kronos Bio reports Q4 results
Seeking Alpha · 03/21 16:41
Recap: Kronos Bio Q4 Earnings
Kronos Bio reported its Q4 earnings on March 21. Kronos Bio beat estimates by 17.0%. The company's revenue was up $2.29 million from the same period last year. The company is expected to announce its earnings Thursday morning. Last quarter the company missed on EPS by $0.03.
Benzinga · 03/21 13:35
Kronos Bio Inc reports results for the quarter ended in December - Earnings Summary
Kronos Bio Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 34 cents per share. Revenue was $2.29 million; analysts expected $1.53 million. Kronos Bio shares had fallen by 3.2% this quarter.
Reuters · 03/21 12:38
Kronos Bio Q4 EPS $(0.43) Beats $(0.52) Estimate, Sales $2.29M Beat $1.52M Estimate, Cash Balance of $175.0M
Kronos Bio reports quarterly losses of $0.43 per share. The company reported quarterly sales of $2.29 million. Kronos Bio beat the analyst consensus estimate of $1.52 million by 50.39%. The company is up 23.21 percent from the same period last year.
Benzinga · 03/21 11:08
BRIEF-Kronos Bio Q4 EPS USD -0.43
Reuters · 03/21 11:05
Press Release: Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
Kronos Bio reports recent business progress and fourth-quarter and full-year 2023 financial results. Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three- days-off schedule in the third quarter of 2024. Second development candidate, KB-9558, is designed to target the KAT domain of p300 in multiple myeloma.
Dow Jones · 03/21 11:05
Press Release: Kronos Bio Reports Recent Business -2-
Three months and year ended December 31, 2018 and 2022. The Company has reported a net loss for the three months ended December 30, 2018. The Company expects to report a loss for each of the three years ending December 31. The company's net loss is $43.2 million for the years ended November 30, 2017 and 2018. The company expects to post a profit for each year ended 2022.
Dow Jones · 03/21 11:05
*Kronos Bio 4Q Rev $2.29M >KRON
Dow Jones · 03/21 11:05
More
Webull provides a variety of real-time KRON stock news. You can receive the latest news about Kronos Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KRON
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.